Compound class:
Antibody
Comment: COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis [2]. Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A [1]. The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial. |
| References |
|
1. Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D. (2014)
Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem, 289 (20): 14392-8. [PMID:24692552] |
|
2. Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W et al.. (2016)
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs, 8 (1): 141-9. [PMID:26390837] |
